Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | Director | May 01, 2024 | May 01, 2024 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 30, 2026 | July 02, 2026 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date May 01, 2024 · Filed May 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-04-30 | Direct | 40,000 |
Reported balance
After 2024-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.
Fulcrum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29 | Direct | 32,000 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,070 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 44,070 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2019 Filed Mar 28, 2019 20:21 UTC | NOVAVAX INC NVAX · Entity 4632 | PurchaseCommon Stock | 22,000 | $0.53 | $11,655.60 |
DisclosureSEC source: 0001209191-19-021625 · doc4.xml · nonDerivative · entry 3 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,000 F2 · ownership.nature: Represents shares attributable to the Reporting Person as indirect holdings held in a trust for the benefit of the Reporting Person's child. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 20:21 UTC | NOVAVAX INC NVAX · Entity 4632 | PurchaseCommon Stock | 22,000 | $0.53 | $11,655.60 |
DisclosureSEC source: 0001209191-19-021625 · doc4.xml · nonDerivative · entry 2 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,000 F1 · ownership.nature: Represents shares attributable to the Reporting Person as indirect holdings held in a trust for the benefit of the Reporting Person's child. Read SEC document |
| March 27, 2019 Filed Mar 28, 2019 20:21 UTC | NOVAVAX INC NVAX · Entity 4632 | PurchaseCommon Stock | 42,000 | $0.53 | $22,251.60 |
DisclosureSEC source: 0001209191-19-021625 · doc4.xml · nonDerivative · entry 1 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:22 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001209191-19-004827 · doc4.xml · derivative · entry 1 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 17, 2020 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| October 31, 2018 Filed Nov 2, 2018 20:41 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 160,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-18-056944 · doc4.xml · derivative · entry 1 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2028-10-31 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the October 31, 2018 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:04 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0001209191-18-003393 · doc4.xml · derivative · entry 1 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-01-09 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 10, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| September 08, 2017 Filed Feb 14, 2018 13:52 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GiftCommon Stock | 46,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009860 · doc5.xml · nonDerivative · entry 3 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rachel K. King 2013 GRAT Disclosed balance after: 0 F2 · ownership.nature: On June 7, 2013, the reporting person contributed 136,281 shares of the issuer's common stock to a grantor retained annuity trust for the benefit of herself and her two adult children. Upon termination of the trust, on September 8, 2017, a total of 46,602 shares were transferred to trusts for the benefit of the adult children. The remaining 89,679 shares were previously distributed to the reporting person and continue to be reported on this form as directly owned. Read SEC document |
| September 08, 2017 Filed Feb 14, 2018 13:52 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GiftCommon Stock | 23,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009860 · doc5.xml · nonDerivative · entry 2 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Langley King 2013 GRAT Disclosed balance after: 23,301 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: On June 7, 2013, the reporting person contributed 136,281 shares of the issuer's common stock to a grantor retained annuity trust for the benefit of herself and her two adult children. Upon termination of the trust, on September 8, 2017, a total of 46,602 shares were transferred to trusts for the benefit of the adult children. The remaining 89,679 shares were previously distributed to the reporting person and continue to be reported on this form as directly owned. Read SEC document |
| September 08, 2017 Filed Feb 14, 2018 13:52 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GiftCommon Stock | 23,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009860 · doc5.xml · nonDerivative · entry 1 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Connor King 2013 GRAT Disclosed balance after: 23,301 F1 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: On June 7, 2013, the reporting person contributed 136,281 shares of the issuer's common stock to a grantor retained annuity trust for the benefit of herself and her two adult children. Upon termination of the trust, on September 8, 2017, a total of 46,602 shares were transferred to trusts for the benefit of the adult children. The remaining 89,679 shares were previously distributed to the reporting person and continue to be reported on this form as directly owned. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 13:50 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-17-001649 · doc4.xml · derivative · entry 1 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 4, 2018 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.